Grown Rogue International (GRUSF) Gross Margin (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Gross Margin came in at 43.23% in Q1 2026, down 382.0% year-on-year from 15.33% in Q1 2025, and down 12.4% quarter-over-quarter from 49.34% in Q4 2025.
Grown Rogue International (GRUSF) Gross Margin (2011 - 2026) Analysis & Trends
Grown Rogue International's Gross Margin history runs 13 years deep, the most recent figure standing at 43.23% for Q1 2026.
- On a quarterly basis, Gross Margin fell 382.0% year-over-year to 43.23% in Q1 2026; TTM through Mar 2026 was 41271727.33%, a 4127177662.0% decrease from a year earlier, with the FY2025 full-year figure at 43.62%, down 612.0% from the prior year.
- Gross Margin retreated to 43.23% in Q1 2026 per GRUSF's latest filing, from 49.34% in the prior quarter.
- Across five years, Gross Margin topped out at 41397182.1% in Q2 2025 and bottomed at 43.23% in Q1 2026.
- The 5-year median for Gross Margin is 49.74% (2024), against an average of 2759860.91%.
- Across the five-year window, Gross Margin slumped 1542 bps in 2024 and surged 2000000000 bps in 2025, its largest moves.
- Year by year, Gross Margin stood at 61.96% in 2022, then gained by 5 bps to 65.17% in 2023, then retreated by 24 bps to 49.74% in 2024, then declined by 1 bps to 49.34% in 2025, then dropped by 12 bps to 43.23% in 2026.
- Per Business Quant, the three latest GRUSF Gross Margin figures stand at 43.23% (Q1 2026), 49.34% (Q4 2025), and 66.81% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 43.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.23% |
| Dec 31, 2025 | 49.34% |
| Sep 30, 2025 | 66.81% |
| Jun 30, 2025 | 41,397,182.10% |
| Mar 31, 2025 | 47.04% |
| Dec 31, 2024 | 49.74% |
| Sep 30, 2024 | 56.11% |
| Jun 30, 2024 | 43.74% |
| Mar 31, 2024 | 48.95% |
| Dec 31, 2023 | 65.17% |
| Oct 31, 2023 | 53.95% |
| Jul 31, 2023 | 46.70% |
| Apr 30, 2023 | 43.26% |
| Jan 31, 2023 | 55.57% |
| Jan 31, 2022 | 61.96% |
| Oct 31, 2021 | 82.76% |
| Jul 31, 2021 | 73.99% |
| Apr 30, 2021 | 39.47% |
| Jan 31, 2021 | 26.65% |
| Oct 31, 2020 | 49.86% |